Please assess the completion status of the following clinical trial:

Trial Title: BIFI-OBESE: Clinical Trial in Paediatric Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. both sexes~2. between 6 and 18 years of age~3. obese, according to the IOTF criteria (Cole TJ et al., 2000)~4. pubertal stage ≥ 2 according to the Tanner stage (Tanner et al., 1961)~5. HOMA-IR \> 2,5 or insulin \> 15 µU/ml~Exclusion Criteria:~1. Adverse reactions to the product or component of the product (allergies...)~2. Genetic obesity (Prader Willi syndrome, Down syndrome), Metabolic obesity (Laurence-biedl syndrome...), endocrinological obesity (Cushinch syndrome, hypotiroidism)~3. Chronic diseases, hepatic or gastroenterological diseases~4. Medical treatment for chronic diseases~5. Probiotic or prebiotic therapies and antibiotic treatment

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Active group Bifidobacterium breve BR03 and B632 (Type: ACTIVE_COMPARATOR): This arm will receive a supplementation of probiotic containing Bifidobacterium breve B632 and Bifidobacterium breve BR03, 15 gtt/die (3x108 CFU/die) once a day.
- Placebo group (Type: PLACEBO_COMPARATOR): This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.

Based on this trial design, predict the completion outcome and termination type (if applicable).